Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)

By sjmartinez • February 13, 2025

Chavez JC, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani C, Lin Y, Riedell PA, Kekre N, de Vos S, Wullf J, Williams CM, Winters J, Kloos IM Dr, Xu H, Neelapu SS. Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12). Blood. 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347. Epub ahead of print. PMID: 39938019.

Tags: Hematology/Oncology, Publications

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review

Smith CE, Sammons SL, Minami CA, Sedrak MS, Magnuson A, O'Connor T, Hshieh TT, Smith S, Ruderman K, Bak K, Lin NU, Freedman RA. Systemic[...]

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers

Shachar EK, Silverstein J, Gornbein J, Salani R, Karlan BY, Chase DM. Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related[...]

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]